Complement C5-blocking Agent in Refractory Dermatomyositis

REFERENCES

1. 1.↵
   1. Leclair V,
   2. Lundberg IE

   . Recent clinical trials in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2017;29:652–9.

   OpenUrl
2. 2.↵
   1. Oddis CV,
   2. Reed AM,
   3. Aggarwal R,
   4. Rider LG,
   5. Ascherman DP,
   6. Levesque MC,
   7. et al.

   Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314–24.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mandel DE,
   2. Malemud CJ,
   3. Askari AD

   . Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis. Int J Mol Sci 2017;18:1084.

   OpenUrl
4. 4.↵
   1. Bohan A,
   2. Peter JB

   . Polymyositis and dermatomyositis. N Engl J Med 1975;292:344–7.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Winthrop KL,
   2. Mariette X,
   3. Silva JT,
   4. Benamu E,
   5. Calabrese LH,
   6. Dumusc A,
   7. et al.

   ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21–40.

   OpenUrl
6. 6.↵
   1. Lahoria R,
   2. Selcen D,
   3. Engel AG

   . Microvascular alterations and the role of complement in dermatomyositis. Brain 2016;139:1891–903.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Pytel P

   . C4d staining as immunohistochemical marker in inflammatory myopathies. Appl Immunohistochem Mol Morphol 2014;22:696–704.

   OpenUrl
8. 8.↵
   1. Couvrat-Desvergnes G,
   2. Masseau A,
   3. Benveniste O,
   4. Bruel A,
   5. Hervier B,
   6. Mussini JM,
   7. et al.

   The spectrum of renal involvement in patients with inflammatory myopathies. Medicine 2014;93:33–41.

   OpenUrl
9. 9.↵
   1. Hofer J,
   2. Rosales A,
   3. Fischer C,
   4. Giner T

   . Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr 2014;2:97.

   OpenUrl
10. 10.↵
    1. Licht C,
    2. Greenbaum LA,
    3. Muus P,
    4. Babu S,
    5. Bedrosian CL,
    6. Cohen DJ,
    7. et al.

    Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061–73.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Takada K,
    2. Bookbinder S,
    3. Furie R,
    4. Oddis C,
    5. Mojcik C,
    6. Bombara M,
    7. et al.

    A pilot study of eculizumab in patients with dermatomyositis. Arthritis Rheum 2002;46 Suppl 9:S489.

    OpenUrlCrossRef